Jim Cramer says Roche's $8.3 billion bid for U.S. biotech firm InterMune means big pharma is thinking big. Cramer says there are so many biotech companies out there losing money as InterMune was, while at the same time companies like Roche, Merck, Pfizer and Glaxo need to make acquisitions for growth. He says the game plan for these companies is to find a biotech that may have a drug breakthrough and is about to get FDA approval. In this case, Roche, the Swiss drugmaker, is hoping to cash in on the pending U.S. approval of California-based InterMune's new drug that treats a deadly lung disease. Roche says it will continue to focus on targeted acquisitions.